Skip to main content
Premium Trial:

Request an Annual Quote

Consortium Receives $8M to Investigate Molecular Roots of Extreme Aggression

NEW YORK (GenomeWeb News) – The European Union has approved a project aimed at determining the causes of extreme aggressive behavior and is providing €6 million ($8 million) to the effort.

Called Aggressotype, the project seeks to find the molecular roots of extreme aggression in children with attention deficit hyperactivity disorder and other "conduct disorders," as well as in the general population. The total cost of the project is about €8.1 million, according to the grant application. The EU funding was awarded as part of the Seventh Framework Programme.

In the application, the researchers said that they will use existing data sets and acquire new data to build a "knowledge chain from molecule to behavior, investigating known and novel genes, gene networks, and their epigenetic interactions, and mapping their mode of action from the molecular via the cellular to the brain-circuit level."

The work, they added, is expected to result in new algorithms that may be useful in predicting aggressive behavior. The algorithms will be validated in existing longitudinal studies in children. Their predictive value for adults will also be tested.

Additionally, Aggressotype will test "non-pharmacological biofeedback for personalized treatment and prevention of overt aggression." New pharmacological compounds for treating aggression will be identified through zebrafish models.

Participating institutions and companies in the project include the University of Leicester, UK; Maastricht University, Netherlands; University of Bergen, Norway; University of Dundee, UK; University of Zurich; University of Ulm, Germany; King's College London; Central Institute of Mental Health, Germany; Decode Genetics; University Medical Center Groningen, Netherlands; Madrid Health Service; Genoway; Genalice; Vall d'Hebron University Hospital Foundation - Research Institute, Spain; University Hospital of Würzburg, Germany; Consortium Institute of Biomedical Research August Pi i Sunyer, Spain; Research Foundation of the State University of New York; Bambino Gesù Children’s Hospital, Italy, View Point; University of Tartu, Estonia; Concentris Research Management; and University of Barcelona, Spain.

The Catholic University Foundation in the Netherlands is coordinating the project.

Dutch software firm Genalice said today that it was awarded €200,000 for work it will carry out as part of the project. The biomedical big data firm will apply its unbiased correlation engine, Genalice Link, to the large, complex datasets to be used as part of Aggressotype.

In a statement, Genalice CTO Hans Karten said, “These data sources are very diverse in nature and consist of, for example, behavioral diagnosis, clinical data … and genetic information. In collaboration with consortium partners we will apply our engine to the data to determine correlations across different sources.

"Furthermore, we will build a relational database that describes all identified correlations that can be used with novel data of a particular source to predict markers in a different source," he said.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.